Research Area
Product Type
United States ( Change Country )
Deforolimus (Ridaforolimus) Chemical Structure
Recommended Products
BEZ235 (NVP-BEZ235)
BEZ235 (NVP-BEZ235)is a dual ATP-competitive phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin (mTOR) inhibitor of p110α, p110γ, p110δ and p110β with IC50 of 4 nM, 5 nM, 7 nM and 75 nM，respectively.
PI-103
PI-103 is a potent, cell-permeable, ATP-competitive PI3K family member inhibitor with IC50 of 2, 8, 20, 26, 48, 83, 88, 150 nM for DNA-PK, p110α, mTORC1, PI3-KC2β, p110δ, mTORC2, p110β, and p110γ, respectively.
Rapamycin (Sirolimus)
Rapamycin also known as Sirolimus & Rapamune is an mTOR inhibitor. Rapamycin Sirolimus inhibits cell motility by suppression of mTOR-mediated pathways.
Temsirolimus (Torisel)
Temsirolimus (Torisel) is a mTOR inhibitor.
Everolimus (RAD001)
Everolimus (RAD001) also known as SDZ-RAD, Certican, Zortress and Afinitorm is an mTOR inhibitor available at Selleck with IC50 of 0.63 nM.
Ku-0063794
Ku-0063794 is an mTOR inhibitor, IC50 ~10 nM for mTORC1 and mTORC2, respectively.
WYE-354
WYE-354 is an mTOR inhibitor with an IC50 of 5 nM.
GSK1059615
GSK1059615 is a pan-PI3K reversible inhibitor,IC50:PI3Kα(0.4 nM), β (0.6 nM),γ (5 nM),δ (2 nM) and mTOR(12 nM).
XL765
XL765 is a mixed mTOR/PI3k inhibitor with IC50 of 157, 39, 113, 9 and 43 nM for mTOR, p110α, β, γ and δ, respectively.
AZD8055
AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mTOR kinase inhibitor with an IC50 of 0.8 nM.
Biological Activity
Deforolimus (Ridaforolimus) is a small-molecule inhibitor of mTOR. It is an immunosuppressant for the treatment of certain cancers. Blocking mTOR creates a starvation-like effect in cancer cells by interfering with cell growth, division, metabolism, and angiogenesis. [1]
References on Deforolimus (Ridaforolimus)
- [1] Recent Patents on Cardiovascular Drug Discovery 2006, 1;85-93
Chemical Information
| Molecular Weight (WM): | 990.21 |
|---|---|
| Formula: | C53H84NO14P |
| CAS No.: | 572924-54-0 |
| Synonyms: |
AP23573, MK-8669
|
| Dissolve in (25°C): | DMSO ≥198mg/mL |
| Water <1mg/mL | |
| Ethanol <1mg/mL | |
| Storage: | 2 years-20°CPowder |
| 1 week-4°Cin DMSO | |
| 1 month-80°in DMSO |
Quality Control & MSDS
Research Area
Notes:
Related Inhibitors
Related Antibodies
Recommended Screening Libraries
Chemical Library
A collection of 864 bioactive compounds
Inhibitor Library
A collection of 481 inhibitors
Kinase Inhibitor Library
A collection of 194 kinase inhibitors
Tyrosine Kinase Inhibitor Library
A collection of 85 tyrosine kinase inhibitors.
FDA Approved Drug Library
A collection of 426 FDA approved drugs
Natural Product Library
A collection of 139 natural products
Chemotherapeutic Agent Library
A collection of 40 chemotherapeutic agents
Epigenetics Compound library
A unique collection of 17 small molecule modulators
Stem Cell Compound library
A unique collection of 47 small molecule inhibitors
GPCR Compound library
A unique collection of 63 GPCR small molecules
Selleck's high quality products have been used in several published research findings, including the following:
Inhibition of glycogen biosynthesis via mTORC1 suppression as an adjunct therapy for Pompe disease.
We have 2 customer reviews of Deforolimus (Ridaforolimus).
- (0)
- (1)
- (1)
- (0)
- (0)
- (0)
- (0)
- (0)
- (0)
Average Customer Review
(2 customer reviews)
-
Click to enlarge
Concentration-time profile in rat serum following administration of deforolimus formulations(10mg/kg) intravenously to rats （mean + SEM）
Concentration-time profile in rat serum following administration of deforolimus formulations(10mg/kg) intravenously to rats （mean + SEM）
Data independently produced by Dr Neal M. Davies of Washington State University Deforolimus (Ridaforolimus) purchased from Selleck
-
Click to enlarge
Breast cancer cells were pretreated with 100ng/ml EGF for 15 min and then treated with the indicated concentrations of Deforolimus for 24 hours.
Breast cancer cells were pretreated with 100ng/ml EGF for 15 min and then treated with the indicated concentrations of Deforolimus for 24 hours.
Data independently produced by Dr Zhang of Tianjin Medical University Deforolimus (Ridaforolimus) purchased from Selleck
This product has been referenced in
Check our customer reviews
Concentration-time profile in rat serum following administration of deforolimus formulations(10mg/kg) intravenously to rats （mean + SEM）
|
Data independently produced by Dr Neal M. Davies of Washington State University
Breast cancer cells were pretreated with 100ng/ml EGF for 15 min and then treated with the indicated concentrations of Deforolimus for 24 hours.
|
Data independently produced by Dr Zhang of Tianjin Medical University
We give free samples and rewards to people who would like to provide us useful scientific data(western blot, etc.) > See Details
Recently Viewed Items
Keywords:buy Deforolimus (Ridaforolimus) | Deforolimus (Ridaforolimus) supplier | purchase Deforolimus (Ridaforolimus) | Deforolimus (Ridaforolimus) cost | Deforolimus (Ridaforolimus) manufacturer | order Deforolimus (Ridaforolimus) | Deforolimus (Ridaforolimus) distributor